We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-16.07%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.14B
AUM Growth
-$212M
Cap. Flow
+$98.4M
Cap. Flow %
8.63%
Top 10 Hldgs %
46.56%
Holding
206
New
51
Increased
51
Reduced
18
Closed
36
Avg Time Held Equity + Options
3 quarters
Top 10 Avg Time Held Equity + Options
4.1 quarters
Top 20 Avg Time Held Equity + Options
4.2 quarters
Avg Time Held Equity only
3.1 quarters
Top 10 Avg Time Held Equity only
4.1 quarters
Top 20 Avg Time Held Equity only
4.3 quarters

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$27.8M
2
HUM icon
Humana
HUM
+$19.1M
3
XLRN
Acceleron Pharma
XLRN
+$15.3M
4
QTNT
Quotient Limited Ordinary Shares
QTNT
+$13.2M
5
MDVN
MEDIVATION, INC.
MDVN
+$12.3M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$68.4M
2
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$12.9M
3
BAX icon
Baxter International
BAX
+$10.1M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$8.54M
5
NVRO icon
NEVRO CORP.
NVRO
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.87%
2 Miscellaneous 6.35%
3 Consumer Staples 0.6%
4 Consumer Discretionary 0.11%
5 Industrials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SIOX
51
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$5.57M 0.49%
60,625
-6,250
-9% -$667K
2015 Q2
3 quarters
ANTH
52
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$5.4M 0.47%
186,520
+62,500
+50% +$1.7M
2013 Q2
11 quarters
MYOK
53
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$5.38M 0.47%
502,894
-9
-0% -$82
2015 Q4
1 quarter
ALDX icon
54
Aldeyra Therapeutics
ALDX
$54.3M
$5.2M 0.46%
1,240,458
– –
2015 Q1
4 quarters
CELG
55
DELISTED
Celgene Corp
CELG
$5M 0.44%
+50,000
New +$5.15M
2016 Q1
0 quarters
NERV icon
56
Minerva Neurosciences
NERV
$120M
$4.98M 0.44%
101,317
– –
2015 Q1
4 quarters
ALDR
57
PUT
DELISTED
Alder Biopharmaceuticals
ALDR
$4.9M 0.43%
+200,000
New +$4.63M
2016 Q1
0 quarters
ABEO icon
58
Abeona Therapeutics
ABEO
$258M
$4.51M 0.4%
70,515
– –
2014 Q4
5 quarters
AMGN icon
59
Amgen
AMGN
$223B
$4.5M 0.39%
30,000
-20,000
-40% -$2.97M
2015 Q3
2 quarters
CASC
60
DELISTED
Cascadian Therapeutics, Inc.
CASC
$4.33M 0.38%
569,020
– –
2013 Q3
10 quarters
AVXS
61
DELISTED
AveXis, Inc. Common Stock
AVXS
$4.09M 0.36%
+150,000
New +$3.28M
2016 Q1
0 quarters
GNCA
62
DELISTED
Genocea Biosciences, Inc.
GNCA
$4M 0.35%
+64,577
New +$2.05M
2016 Q1
0 quarters
ASMB icon
63
Assembly Biosciences
ASMB
$414M
$3.99M 0.35%
66,250
– –
2015 Q1
4 quarters
ARCT icon
64
Arcturus Therapeutics
ARCT
$342M
$3.9M 0.34%
146,896
– –
2015 Q4
1 quarter
SPNC
65
DELISTED
Spectranetics Corp
SPNC
$3.88M 0.34%
267,070
-2,500
-0.9% -$34.6K
2015 Q4
1 quarter
ANIP icon
66
ANI Pharmaceuticals
ANIP
$1.63B
$3.84M 0.34%
114,060
+101,260
+791% +$3.43M
2014 Q4
5 quarters
NDRM
67
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$3.81M 0.33%
270,000
– –
2014 Q4
5 quarters
IMMU
68
DELISTED
Immunomedics Inc
IMMU
$3.55M 0.31%
1,420,000
+1,220,000
+610% +$2.74M
2015 Q4
1 quarter
OTIC
69
DELISTED
Otonomy, Inc.
OTIC
$3.52M 0.31%
235,986
+30,000
+15% +$471K
2014 Q3
6 quarters
ZLTQ
70
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$3.31M 0.29%
+122,000
New +$2.88M
2016 Q1
0 quarters
FWP
71
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$3.17M 0.28%
+26,614
New +$2.98M
2016 Q1
0 quarters
OMER icon
72
Omeros
OMER
$1.37B
$3.07M 0.27%
+200,000
New +$2.43M
2016 Q1
0 quarters
SUPN icon
73
Supernus Pharmaceuticals
SUPN
$2.45B
$3.05M 0.27%
+200,000
New +$2.61M
2016 Q1
0 quarters
WBA icon
74
DELISTED
Walgreens Boots Alliance
WBA
$2.97M 0.26%
35,292
– –
2013 Q3
10 quarters
ACAD icon
75
PUT
Acadia Pharmaceuticals
ACAD
$3.21B
$2.8M 0.25%
+200,000
New +$4.36M
2016 Q1
0 quarters
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2016 Portfolio in Review

As of Q1 2016, Perceptive Advisors held 206 positions worth $1.14B, down 16% from $1.35B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $98.4M of net new capital in Q1 2016, opening 51 new positions and adding to 51 existing holdings. Its largest new stake was Humana: 110,000 shares worth $20.1M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Teva Pharmaceutical Industries Limited, an estimated $12.9M trimmed.

  • Perceptive Advisors's largest Q1 2016 buy was Humana: 110,000 shares worth $20.1M.
  • Perceptive Advisors added most to Sarepta Therapeutics in Q1 2016, an estimated $27.8M increase.
  • Perceptive Advisors's biggest Q1 2016 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $12.9M.
  • Perceptive Advisors fully exited DYAX CORPORATION in Q1 2016, selling an estimated $68.4M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $1.14B portfolio in Q1 2016.
  • Perceptive Advisors opened 51 new positions and closed 36 in Q1 2016.
  • Perceptive Advisors's portfolio value fell 16% quarter-over-quarter to $1.14B.

Based on Perceptive Advisors's 13F filing for Q1 2016, filed 16 May 2016.